Constellation Pharmaceuticals to Participate in Investor Conference
10 juin 2020 11h30 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Announces Appointment of Dr. Jeffrey Humphrey as Chief Medical Officer
08 juin 2020 08h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
Constellation Pharmaceuticals to Participate in Investor Conference
29 mai 2020 09h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., May 29, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals to Host Analyst / Investor Event to Discuss Update of MANIFEST Clinical Trial for CPI-0610
28 mai 2020 12h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
Constellation Pharmaceuticals Provides Update of Preliminary Data for CPI-0610 in Three EHA Abstracts
14 mai 2020 08h00 HE
|
Constellation Pharmaceuticals , Inc.
Continued high rate of SVR35 in 1L patients: 72% at 12 weeks and 67% at 24 weeksSVR35 responses and transfusion dependence conversion observed in 2L monotherapy patients Improvement in bone marrow...
Constellation Pharmaceuticals Announces First-Quarter 2020 Financial Results
06 mai 2020 07h00 HE
|
Constellation Pharmaceuticals , Inc.
EHA abstracts to publish on May 14 with an interim update across the MANIFEST trial cohortsConstellation to provide an additional interim update from MANIFEST at EHA in mid-June Company continues to...
Constellation Pharmaceuticals to Participate in Two Investor Conferences
05 mai 2020 14h06 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals to Host Conference Call to Discuss First Quarter 2020 Results
28 avr. 2020 09h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
Constellation Pharmaceuticals Announces Appointment of Dr. Richard Levy to Board of Directors
06 avr. 2020 07h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., April 06, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to...
Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2019 Financial Results
10 mars 2020 16h12 HE
|
Constellation Pharmaceuticals , Inc.
Clinical data presented at 2019 American Society of Hematology (ASH) annual meeting suggested that CPI-0610 could offer meaningful benefits beyond standard of care in myelofibrosis In addition to...